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ABSTRACT
Background: Atrial ﬁbrillation (AF) is associated with
a high risk of stroke and may often be asymptomatic.
AF is commonly undiagnosed until patients present
with sequelae, such as heart failure and stroke. Stroke
secondary to AF is highly preventable with the use of
appropriate thromboprophylaxis. Therefore, early
identiﬁcation and appropriate evidence-based
management of AF could lead to subsequent stroke
prevention. This study aims to determine the feasibility
and impact of a community pharmacy-based screening
programme focused on identifying undiagnosed AF in
people aged 65 years and older.
Methods and analysis: This cross-sectional study of
community-based screening to identify undiagnosed
AF will evaluate the feasibility of screening for AF using
a pulse palpation and handheld single-lead
electrocardiograph (ECG) device. 10 community
pharmacies will be recruited and trained to implement
the screening protocol, targeting a total of 1000
participants. The primary outcome is the proportion of
people newly identiﬁed with AF at the completion of the
screening programme. Secondary outcomes include
level of agreement between the pharmacist’s and the
cardiologist’s interpretation of the single-lead ECG;
level of agreement between irregular rhythm identiﬁed
with pulse palpation and with the single-lead ECG.
Process outcomes related to sustainability of the
screening programme beyond the trial setting,
pharmacist knowledge of AF and rate of uptake of
referral to full ECG evaluation and cardiology review
will also be collected.
Ethics and dissemination: Primary ethics approval
was received on 26 March 2012 from Sydney Local
Health District Human Research Ethics
CommitteedConcord Repatriation General Hospital
zone. Results will be disseminated via forums
including, but not limited to, peer-reviewed publication
and presentation at national and international
conferences.
Clinical trials registration
number: ACTRN12612000406808.
INTRODUCTION
Atrial ﬁbrillation
Atrial ﬁbrillation (AF) is the most common
heart arrhythmia, with a lifetime risk of
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ARTICLE SUMMARY
Article focus
- Describes the protocol for a community-based
screening programme to identify previously
undetected AF in adults aged 65 years and
older in the community, for stroke prevention.
Key messages
- Early identiﬁcation of AF would allow for timely
referral for medical review and subsequent
initiation of appropriate evidence-based throm-
boprophylaxis to prevent stroke.
- The efﬁcacy of screening for AF in a community
setting is yet to be tested in a well-designed
clinical trial.
Strengths and limitations of this study
- The main strengths of this study are that it uses
a simple community-focused strategy using
innovative technology to screen for AF, which
may be suitable for widespread implementation.
The technology delivers a single-lead electrocar-
diograph available for immediate interpretation
and corroboration by an expert cardiologist
remotely.
- The sample size of 1000 will inform the
design and reﬁnement of a future large-scale
intervention and implementation study.
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Open Access Protocol1:4 for adults worldwide,
1 affecting at least 240000
Australians.
2 Prevalence rises with age from approxi-
mately 1% of the whole population to 5% in those older
than 65 years.
3 People with AF are up to seven times
more likely to have a stroke than the general population
and up to three times more likely to experience heart
failure. AF-related strokes are also likely to be more
severe.
2 In addition, one in every six strokes is AF
related,
4 and more than 45000 hospitalisations are
caused by AF, with direct annual health system costs in
Australia of $874 million.
2
Many people in the general population are unaware
that they have AF, with ﬁrst diagnosis being made when
they are admitted to hospital with a stroke or transient
ischaemic attack.
5 Our group undertook a review of
12-lead electrocardiograph (ECG) recordings taken in
a preadmission clinic where ECGs are routinely
performed on patients older than 40 years. Of the 2802
ECGs reviewed, AF was incidentally found in 12 patients
(0.4%) and previously diagnosed in 100 patients
(3.6%).
6 Thromboprophylaxis based on CHADS2 scores
was indicated in 10 of the 12 newly identiﬁed patients
with AF, according to evidence-based guidelines.
7 Addi-
tionally, 10 of the 12 newly identiﬁed patients with AF
were asymptomatic. Another AF screening programme
in the UK general practices identiﬁed previously
unknown AF in 1.6% of screened patients, using pulse
palpation and ECG.
8
Furthermore, patients have poor knowledge of AF
management and treatment, and the risks associated
with AF.
9 In a recent survey conducted by the American
Heart Association, approximately 50% of those surveyed
with AF did not know that they were at increased risk of
stroke.
10
Stroke is highly preventable in AF with the use of
appropriate thromboprophylaxis.
11 Therefore, early
identiﬁcation and appropriate evidence-based manage-
ment of AF
7 could lead to subsequent stroke prevention,
signiﬁcant reduction in the overall stroke burden and
substantial savings to the health system.
AF screening in community pharmacies
Community pharmacies provide an ideal location,
and an appropriate health professional/community
interface, to screen people for AF. Approximately 90% of
the Australian population visits a community pharmacy
each year making it one of the most accessible health-
care services in the community.
12 13 Additionally,
patients older than 65 years with chronic conditions
generally visit their community pharmacy at least
monthly in order to ﬁll prescriptions.
14
Pharmacists are actively involved in the triage of
medical problems presenting in the community, many of
which are potentially serious.
15 Community pharmacy
also has a leading role in the management of many
chronic medical problems, including cardiovascular
disease management and general health screening.
16e18
Recently, various professional practice incentives under
the 5th Community Pharmacy Agreement have provided
opportunities for community pharmacists to increase
their role in chronic disease management.
19 Involve-
ment of community pharmacists in a screening project
such as the one proposed here would enable
performance of their obligations with regard to these
incentives.
METHODS AND ANALYSIS
Design
This study is a cross-sectional study of community-based
screening to identify undiagnosed AF (ﬁgure 1)
(ACTRN12612000406808). Screening will be offered in
10 community pharmacies in Sydney, Australia, and will
be performed by the pharmacist on duty.
Preintervention
Local pharmacies will be invited to volunteer to partici-
pate in the study with a total of 10 pharmacies to be
recruited. Community pharmacists working in these
pharmacies will be educated regarding AF. Education
will include the causes of AF, symptoms and evidence-
based management, the health risks associated with AF,
self-care management and cardiovascular risk reduction.
The pharmacist will also be trained to obtain a relevant
brief medical history related to cardiovascular disease,
undertake pulse palpation, operate the AliveCor Heart
Monitor for iPhone (handheld single-lead ECG)
20
(ﬁgure 2) and interpret the single-lead ECG trace
recording. Training of pharmacists will be undertaken
Figure 1 SEARCH-AF study design.
2 Lowres N, Freedman SB, Redfern J, et al. BMJ Open 2012;2:e001355. doi:10.1136/bmjopen-2012-001355
Screening Education And Recognition in Community pHarmacies of Atrial Fibrillationusing a structured training module, using a combination
of online, centralised and onsite training, designed and
delivered by a senior cardiologist, specialist nurse,
specialist pharmacist and physiotherapist. Pharmacists
will be required to demonstrate competency in essential
skills and knowledge relating to AF diagnosis prior to
initiating community pharmacy screening. Participating
pharmacists will be eligible to claim Continuing Profes-
sional Development points on completion of the
training module.
Prior to commencement of the screening programme,
participating pharmacists will provide information
about the SEARCH-AF programme to the general prac-
titioners in their local area. The information will outline
the screening process, the pharmacist’s involvement and
the referral pathway for patients as outlined in the
protocol.
A quality improvement framework is included to aid
the reﬁnement of the project through a continuous
improvement design of evaluation, adjustment and re-
evaluation. To aid this process, collaborative links with
a stakeholder team will be developed, including repre-
sentatives from consumer groups, general practitioners,
the Medicare Local Network, pharmacists and the
Pharmacy Guild.
Study population
All members of the general public attending pharmacies
will be eligible to participate if they are aged 65 years or
older, and if they provide informed consent. Those with
a diagnosis of a severe coexisting medical condition that
would prevent participation (eg, severe dementia or
terminal illness) will be excluded from the study. This
community sample is reasonably representative of
the general population, as approximately 90% of the
population visit pharmacies each year.
12 13
Interventions
People eligible for screening will be asked by the
community pharmacist if they are interested in partici-
pating in the study and provided with written informa-
tion about the study. This will include explanation of the
process of the screening including the sharing of infor-
mation with their general practitioner and that ECGs
collected during the screening process will be read by
a cardiologist at Concord Hospital. Written and
informed consent from all participants will be obtained
by the pharmacist, prior to conducting the screening
assessment.
Availability of screening to the general public aged
65 years and older will be communicated via posters or
ﬂyers located within the pharmacy and at the entrance
to the pharmacy. The pharmacist may also directly
approach people in the pharmacy to invite them to
undertake AF screening. There will be no charge for
participation in the AF screening programme. Partici-
pants will also be welcome to tell their family and friends
about the screening programme. The intervention ﬂow
chart is displayed in ﬁgure 3.
Screening protocol
< The screening will be approximately 5e10 min
duration.
< Screening will consist of an initial brief medical
history, including pharmacotherapy and screen of AF
symptoms. Pharmacists will perform a pulse palpation
and record the result, then proceed to assess cardiac
rhythm using the AliveCor iPhone handheld single-
lead ECG device for 30e60 s.
< The ECG record with a unique identiﬁcation number
will be transmitted by wireless connection on a secure
server to an iCloud by the AliveCor software. The ECG
record is only accessible by the cardiologist who will
assess each ECG.
< The pharmacist will advise the participant of the
suspected diagnosis and ensure they understand it is
not a deﬁnitive diagnosis and that the ECG will be
reviewed by the cardiologist to either rule-out or rule-
in the provisional diagnosis.
< Every participant will be provided with written
information on AF and how to check their pulse at
home.
< For every person screened, the pharmacist will send
a letter to their general practitioner (GP) informing
that their patient has been screened for AF, stating
the suspected diagnosis, information regarding the
research study, copies of the AF education handouts
provided to the patient and outline how to contact
the investigators if required. The letter will state that
the research cardiologist will review the ECG and will
contact the GP directly to advise if there are any
abnormalities noted.
Figure 2 AliveCor iPhone ECG.
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< The pharmacist will counsel the participant and
advice that the SEARCH-AF team will contact them
directly once the ECG is reviewed.
< The pharmacist will inform the SEARCH-AF team of
the suspected diagnosis within 24 h.
< The ECG will be reviewed by the SEARCH-AF
cardiologist within 24 h.
< The participant will be contacted directly by the
SEARCH-AF team to advise them of their result within
2e3 working days.
< The SEARCH-AF team will call the GP to discuss the
diagnosis and send a letter, which will include a copy
of the ECG recording. If required, the letter will
include an invitation to refer their patient for a full
assessment at the Concord Hospital cardiology clinic
or any other cardiology service of their choosing.
< The pharmacist will call the participant approxi-
mately 1 month after the date of screening, to
ensure they have not been lost to follow-up.
Protocol if AF is not suspected from the screening
< All ECG’s will be reviewed by the research
cardiologist.
< Those participants with an abnormal rhythm, not
previously identiﬁed by the pharmacist, will be
contacted directly by the SEARCH-AF team, coun-
selled regarding the diagnosis and advised to return
to their GP to discuss the next phase of their
management. The SEARCH-AF team will call the GP
to discuss the diagnosis and send a letter outlining
the provisional diagnosis, including a copy of the
ECG recording, and an invitation to refer their
patient for a full assessment at the Concord Hospital
cardiology clinic or any other cardiology service of
their choosing.
Protocol if a history of AF is known prior to the screening
< The pharmacist will send a letter to the participant’s
GP informing them that their patient was screened
for AF, stating if they were in sinus rhythm or AF on
the day of the screening.
< All ECG’s will be reviewed by the research
cardiologist.
< If an abnormality other than AF is identiﬁed, the
following will occur: The participant will be contacted
directly by the SEARCH-AF team, counselled
regarding the diagnosis and advised to return to
their GP to discuss the next phase of their manage-
ment. The SEARCH-AF team will call the GP to
discuss the diagnosis and send a letter outlining the
provisional diagnosis, including a copy of the ECG
recording, and an invitation to refer their patient for
a full assessment at the Concord Hospital cardiology
clinic or any other cardiology service of their
choosing.
Figure 3 Intervention ﬂow chart.
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cardiology clinic, the full assessment will be performed
by a Cardiologist, according to standard cardiology
practice, and will include a 12-lead ECG. If appropriate,
the patient may be commenced on appropriate throm-
boprophylaxis, according to evidence-based guidelines.
7
Quality processes
The ability and accuracy of the pharmacist in interpre-
tation of the ECG will be continually monitored. After
reviewing each ECG, the research team will contact the
pharmacist directly if an incorrect interpretation has
been made. This will allow for feedback, mentoring and
further training to improve the pharmacist’s skill.
Study outcomes
Primary outcome
< Proportion of screened subjects with newly identiﬁed
AF in a community sample aged 65 years and older
(determined from the cardiologists interpretation of
the single-lead ECG)
Secondary outcomes
< The level of agreement between the pharmacist’s
interpretations of the single-lead ECG compared with
the cardiologist’s interpretation of the single-lead
ECG.
< The level of agreement for identiﬁcation of an
irregular rhythm between pulse palpation by the
pharmacist and the cardiologist’s interpretation of
the single-lead ECG taken from the AliveCore iPhone
ECG monitor.
< Proportion of participants that remain in AF, from the
positive diagnosis from the single-lead ECG from the
AliveCore iPhone ECG monitor to the 12-lead ECG
performed during the cardiology review.
Process measures
A detailed process evaluation will be undertaken to
better appreciate factors that might inﬂuence sustain-
ability beyond the trial setting. After the ﬁnal screening
is complete, all participating pharmacists and
a subsample of approximately 10 GP’s involved in the
care of the participants will be asked to complete
a survey that will explore the barriers and enablers to the
screening processes in the SEARCH-AF programme, and
the effects it has had on the reported practice of the
healthcare professionals involved with the participant.
We will review the rate of uptake of referral to full ECG
evaluation and cardiology review. In addition, we will
evaluate the skills and knowledge of AF in all pharma-
cists involved with the screening intervention, prior to
training and at the end of the screening programme.
Statistical considerations
Primary analyses will be conducted using SPSS for
Windows (V.19.0). New episodes of AF will be expressed
as true positives divided by total number screened with
accompanying 95% CIs. A sample size of 1000 will
provide a CI of 60.8% assuming an incidence of 1.6%.
c
2 tests will be used to compare new cases by gender and
to identify associations between AF incidence and age
group or AF risk factors. Two-tailed p values of <0.05 will
be considered signiﬁcant.
ETHICS AND DISSEMINATION
This study received formal ethical approval on 26 March
2012 from the Sydney Local Health District Human
Research Ethics CommitteedConcord Repatriation
General Hospital zone. National Health and Medical
Research Council ethical guidelines for human research
will be adhered to, and written and informed consent
will be obtained from all participants. The study will be
administered by the Anzac Research Institute. Imple-
mentation and conduct of the study will be monitored by
the project management committee (authors) who have
extensive experience in qualitative research and
conducting clinical trials in both cardiovascular disease
and community pharmacies. The results of this study will
be disseminated via the usual scientiﬁc forums,
including peer-reviewed publication and presentations
at international conferences.
CONCLUSIONS
AF is prevalent, affecting approximately 5% of those
aged 65 years and older. Unrecognised AF is generally
not associated with symptoms and raised resting heart
rate. Those with unrecognised AF usually have stroke
risk scores (ie, CHADS2 scores) high enough to warrant
anticoagulation, which suggests that there are appre-
ciable numbers of the well elderly in the community who
would beneﬁt from early recognition of AF through
simple detection programmes, such as pulse palpation
and recording an ECG, followed by thromboprophylaxis
to prevent future stroke.
This cross-sectional study aims to determine the feasi-
bility and impact of a community pharmacy-based
screening, using innovative technology, focused on iden-
tifying people with undiagnosed AF, with onward referral
to their GP for appropriate medical management of AF.
The study also aims to explore the role of pharmacists in
ongoing management of AF, as well their role in raising
AF awareness in the general public. The study will inform
the design and reﬁnement of a future intervention for
large-scale research and implementation.
The ﬁndings of this study will have broad implications
for the general population aged 65 years and older with
undiagnosed AF. We anticipate that this study will
demonstrate that it is possible to identify and treat
people in the community who were not previously
known to have AF, thus greatly reducing the risk of
stroke.
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